Media Highlights
Infection Main Cause of Nonrelapse Deaths With CAR T-Cell Therapy
December 19, 2023
Dr. Jay Spiegel is quoted and identified as a co-author of a study that he presented at ASH 2023. His study showed that CAR T-cell therapy is generally safe even in high-risk patients, but that there remains a significant risk for opportunistic infection, typically early in the post-CAR process.
